[go: up one dir, main page]

MA29807B1 - Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques. - Google Patents

Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques.

Info

Publication number
MA29807B1
MA29807B1 MA30783A MA30783A MA29807B1 MA 29807 B1 MA29807 B1 MA 29807B1 MA 30783 A MA30783 A MA 30783A MA 30783 A MA30783 A MA 30783A MA 29807 B1 MA29807 B1 MA 29807B1
Authority
MA
Morocco
Prior art keywords
phenyl
disorders
oxadiazol
derivatives
processes
Prior art date
Application number
MA30783A
Other languages
English (en)
Inventor
Stefanie Keil
Patrick Bernardelli
Matthias Urmann
Hans Matter
Wolfgang Wendler
Maike Glien
Karen Chandross
Lan Lee
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35809809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29807(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA29807B1 publication Critical patent/MA29807B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)

Abstract

L'INVENTION CONCERNE DES DÉRIVÉS DE PHÉNYL-[1,2,4]-OXADIAZOL-5-ONE À GROUPE PHÉNYLE SOUS TOUTES LEURS FORMES STÉRÉOISOMÈRES ET LEURS MÉLANGES DANS DES PROPORTIONS QUELCONQUES, AINSI QUE LES SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET LES FORMES TAUTOMÈRES DE CEUX-CI QUI EXERCENT UNE ACTIVITÉ AGONISTE SUR LES RÉCEPTEURS PPAR$G(D). L'INVENTION DÉCRIT AINSI DES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE (I), DANS LAQUELLE LES RADICAUX SONT TELS QUE DÉFINIS DANS LA DESCRIPTION, AINSI QUE LES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE CEUX-CI ET LES PROCÉDÉS UTILISÉS POUR LES OBTENIR. CES COMPOSÉS SONT UTILISÉS POUR TRAITER ET/OU PRÉVENIR LES TROUBLES DU MÉTABOLISME DES ACIDES GRAS, LES TROUBLES DE L'UTILISATION DU GLUCOSE, LES TROUBLES IMPLIQUANT L'INSULINORÉSISTANCE ET LA DÉMYÉLINISATION, AINSI QUE D'AUTRES TROUBLES NEURODÉGÉNÉRATIFS DU SYSTÈME NERVEUX CENTRAL ET PÉRIPHÉRIQUE.
MA30783A 2005-09-29 2008-03-24 Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques. MA29807B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05021235 2005-09-29

Publications (1)

Publication Number Publication Date
MA29807B1 true MA29807B1 (fr) 2008-09-01

Family

ID=35809809

Family Applications (2)

Application Number Title Priority Date Filing Date
MA30780A MA29804B1 (fr) 2005-09-29 2008-03-24 Derives de phenyl-et pyridyl-1,2,4-oxadiazolone renfermant un groupe phenyle, procedes pour leur preparation et leur utilisation en tant qu'agents pharmaceutiques
MA30783A MA29807B1 (fr) 2005-09-29 2008-03-24 Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA30780A MA29804B1 (fr) 2005-09-29 2008-03-24 Derives de phenyl-et pyridyl-1,2,4-oxadiazolone renfermant un groupe phenyle, procedes pour leur preparation et leur utilisation en tant qu'agents pharmaceutiques

Country Status (31)

Country Link
US (3) US7834030B2 (fr)
EP (2) EP1931660B1 (fr)
JP (2) JP2009509986A (fr)
KR (2) KR20080048520A (fr)
CN (2) CN101273036A (fr)
AR (2) AR056541A1 (fr)
AT (1) ATE537167T1 (fr)
AU (2) AU2006299092A1 (fr)
BR (2) BRPI0616465A2 (fr)
CA (2) CA2624105C (fr)
CR (1) CR9784A (fr)
CY (1) CY1113376T1 (fr)
DK (1) DK1931660T3 (fr)
DO (2) DOP2006000204A (fr)
EC (1) ECSP088323A (fr)
ES (1) ES2392181T3 (fr)
IL (2) IL190228A0 (fr)
MA (2) MA29804B1 (fr)
MY (2) MY149182A (fr)
NO (2) NO20081370L (fr)
NZ (2) NZ566875A (fr)
PE (2) PE20070545A1 (fr)
PL (1) PL1931660T3 (fr)
PT (1) PT1931660E (fr)
RU (2) RU2008112201A (fr)
SI (1) SI1931660T1 (fr)
TN (1) TNSN08145A1 (fr)
TW (2) TW200811154A (fr)
UY (2) UY29830A1 (fr)
WO (2) WO2007039172A1 (fr)
ZA (1) ZA200801630B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586573B1 (fr) * 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, procédé pour leur préparation, usage comme agents pharmaceutiques
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
CA2954376C (fr) 2006-10-16 2019-06-11 Bionomics Limited Nouveaux composes anxiolytiques
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20210130285A1 (en) * 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
US10793515B2 (en) * 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
CA2771278A1 (fr) 2009-08-26 2011-03-03 Sanofi Nouveaux hydrates de fluoroglycoside heteroaromatiques cristallins, substances pharmaceutiques comprenant ces composes et leur utilisation
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011138751A2 (fr) 2010-05-04 2011-11-10 Pfizer Inc. Dérivés hétérocycliques destinés au traitement de maladies
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN103502219A (zh) 2011-03-02 2014-01-08 生态学有限公司 作为治疗剂的新型小分子
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012151640A1 (fr) 2011-05-12 2012-11-15 Bionomics Limited Procédés pour la préparation de naphtyridines
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
AU2013210394A1 (en) * 2012-01-18 2014-08-14 Daiichi Sankyo Company,Limited Substituted phenylazole derivative
US20150166528A1 (en) 2012-06-14 2015-06-18 Basf Se Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests
US10258672B2 (en) 2014-10-09 2019-04-16 Case Western Reserve University Compositions and methods of treating root avulsion injury
CN106616029B (zh) * 2016-12-08 2020-05-01 西南大学 一种提高虹鳟抗病能力的饲料添加剂及其制备方法
CN108976150B (zh) * 2017-06-05 2022-11-18 重庆博腾制药科技股份有限公司 一种3-乙基-4-氟苯腈的制备方法
CA3064463A1 (fr) * 2017-07-11 2019-01-17 Case Western Reserve University Compositions et methodes pour traiter les maladies de la myeline
JP7417318B1 (ja) 2022-12-28 2024-01-18 Ｔｈｒｅｅ Ｒｉｖｅｒｓ株式会社 濾過器及び飲料抽出器

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
KR100620337B1 (ko) * 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
ES2277842T3 (es) * 1999-06-18 2007-08-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y de ariloxazolidindiona.
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
BRPI0211844B8 (pt) * 2001-08-10 2021-05-25 Nippon Chemiphar Co composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
WO2003072100A1 (fr) * 2002-02-25 2003-09-04 Eli Lilly And Company Modulateurs du recepteur active du proliferateur des peroxysomes
US20070105959A1 (en) 2003-03-11 2007-05-10 Shinya Kusuda Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient
JPWO2005054213A1 (ja) 2003-12-02 2007-12-06 塩野義製薬株式会社 ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
EP1586573B1 (fr) * 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, procédé pour leur préparation, usage comme agents pharmaceutiques
EP1735303B1 (fr) * 2004-04-01 2011-04-27 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee

Also Published As

Publication number Publication date
US7851493B2 (en) 2010-12-14
EP1931660A2 (fr) 2008-06-18
NO20081370L (no) 2008-06-17
IL190227A (en) 2015-05-31
CY1113376T1 (el) 2016-06-22
CA2624093A1 (fr) 2007-04-12
EP1934206B1 (fr) 2011-12-14
DOP2006000204A (es) 2007-03-31
CA2624105A1 (fr) 2007-04-12
MA29804B1 (fr) 2008-09-01
US7834030B2 (en) 2010-11-16
CR9784A (es) 2008-05-05
BRPI0616465A2 (pt) 2011-06-21
ES2392181T3 (es) 2012-12-05
DOP2006000205A (es) 2007-03-31
RU2008112201A (ru) 2009-10-10
PL1931660T3 (pl) 2012-12-31
BRPI0616457A2 (pt) 2011-06-21
IL190227A0 (en) 2009-09-22
UY29829A1 (es) 2007-04-30
US20080262036A1 (en) 2008-10-23
MY149182A (en) 2013-07-31
JP2009509986A (ja) 2009-03-12
UY29830A1 (es) 2007-04-30
KR20080048520A (ko) 2008-06-02
AU2006299086A1 (en) 2007-04-12
CN101268069A (zh) 2008-09-17
PT1931660E (pt) 2012-10-30
JP2009509989A (ja) 2009-03-12
DK1931660T3 (da) 2012-11-05
NZ566875A (en) 2010-06-25
WO2007039172A1 (fr) 2007-04-12
AR056203A1 (es) 2007-09-26
TW200811154A (en) 2008-03-01
WO2007039178A2 (fr) 2007-04-12
SI1931660T1 (sl) 2012-12-31
JP5183479B2 (ja) 2013-04-17
AR056541A1 (es) 2007-10-10
IL190228A0 (en) 2009-09-22
EP1934206A1 (fr) 2008-06-25
AU2006299092A1 (en) 2007-04-12
EP1931660B1 (fr) 2012-08-01
TNSN08145A1 (en) 2009-07-14
CA2624105C (fr) 2014-02-18
WO2007039178A3 (fr) 2007-09-13
ZA200801630B (en) 2009-01-28
KR20080048494A (ko) 2008-06-02
RU2008112202A (ru) 2009-10-10
PE20070768A1 (es) 2007-08-22
US20080287409A1 (en) 2008-11-20
PE20070545A1 (es) 2007-06-15
MY148982A (en) 2013-06-28
US20090281084A1 (en) 2009-11-12
CN101273036A (zh) 2008-09-24
TW200728293A (en) 2007-08-01
ECSP088323A (es) 2008-04-28
NZ566878A (en) 2010-07-30
KR101342415B1 (ko) 2013-12-17
TWI398436B (zh) 2013-06-11
ATE537167T1 (de) 2011-12-15
NO20081367L (no) 2008-06-13

Similar Documents

Publication Publication Date Title
MA29807B1 (fr) Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques.
MA29805B1 (fr) Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques
MA30981B1 (fr) Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments
MA31865B1 (fr) Dérivés isoxazolo-pyridine
MA32705B1 (fr) Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
MA29809B1 (fr) N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques
MA32323B1 (fr) Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA30073B1 (fr) Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA42442B1 (fr) Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate
MA31447B1 (fr) Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
MA29810B1 (fr) 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA34359B1 (fr) Dérivés de carbamate d'hexafluoroisopropyle, leur préparation et leur application thérapeutique
MA27754A1 (fr) Pyrimidinones substituees
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
MA34308B1 (fr) Triazolopyridines substituées
MA32108B1 (fr) Derives d'indazole
MA32506B1 (fr) Nouveaux composes
MA46342A (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation